Streetbeat News

Stock Prices

CUBI

Levi & Korsinsky has announced a class action lawsuit against Customers Bancorp, Inc. (NYSE:CUBI) with a lead plaintiff deadline of January 31, 2025. Investors who suffered losses are encouraged to seek potential recovery under federal securities laws.

Portfolio Pulse from

January 06, 2025 | 12:45 pm

WOLF

A class action lawsuit has been filed against Wolfspeed, Inc. (NYSE:WOLF) for potential recovery under federal securities laws. Investors who suffered losses are encouraged to join the suit.

Portfolio Pulse from

January 06, 2025 | 12:45 pm

QUIK

QuickLogic Corporation (NASDAQ: QUIK) will participate in the 27th Annual Needham Growth Conference and the virtual Oppenheimer 10th Annual Emerging Growth Conference in early 2025.

Portfolio Pulse from

January 06, 2025 | 12:45 pm

AAPL

NVDA

TSM

Chip stocks, including Nvidia and TSMC, are surging in premarket trading following Foxconn's record fourth-quarter revenue, driven by AI technology demand.

Portfolio Pulse from

January 06, 2025 | 12:45 pm

NVDA

Nvidia's stock is rising due to strong demand in the AI sector, as indicated by Taiwan's Foxconn. This demand could drive Nvidia's stock even higher.

Portfolio Pulse from

January 06, 2025 | 12:45 pm

KYTX

A class action lawsuit has been filed against Kyverna Therapeutics, Inc. (NASDAQ:KYTX) with a deadline of February 7, 2025, for investors to join. The lawsuit is related to potential recovery under federal securities laws.

Portfolio Pulse from

January 06, 2025 | 12:45 pm

CNDT

MarketBeat highlights an opportunity for investors to capitalize on ultra-low spreads between value and growth stocks, with Goldman Sachs' strategist suggesting value stocks as strong options for 2025 due to their growth potential and minimized downside risk.

Portfolio Pulse from

January 06, 2025 | 12:45 pm

NTLA

Intellia Therapeutics announced inducement grants to three new employees under its 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

Portfolio Pulse from

January 06, 2025 | 12:45 pm

VYNE

VYNE Therapeutics has completed enrollment for its Phase 2b trial of VYN201 gel, aimed at treating nonsegmental vitiligo. Results from the 24-week trial are expected in mid-2025.

Portfolio Pulse from

January 06, 2025 | 12:45 pm

AZN

A class action lawsuit has been filed against AstraZeneca PLC (NASDAQ:AZN) seeking recovery for investors who suffered losses. Investors are encouraged to contact Levi & Korsinsky for more information.

Portfolio Pulse from

January 06, 2025 | 12:45 pm